Active Ingredient: FENTANYL
(Hérité de ABSTRAL 200 microgrammes) Despite hERG inhibition, Fentanyl at clinically, studies suggest that standard doses (2 µg/kg) do not affect QT in healthy patients, but prolongation has been reported at high doses (5 µg/kg) or in patients with pre-existing cardiac pathology.
https://doi.org/10.1093/bja/aet412, https://doi.org/10.1186/s12871-024-02702-7, https://doi.org/10.2174/1574886311207040262